```
=> fil cap
FILE 'CAPLUS' ENTERED AT 15:26:14 ON 26 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```


FILE COVERS 1907 - 26 Nov 2008 VOL 149 ISS 22
FILE LAST UPDATED: 25 Nov 2008 (20081125/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> d que l9
L1                  STR
```



Page 1-A









Page 2-A
VAR G1=23-2 25-3/25-2 23-3/18-2 22-3
REP G2=(0-2) A
REP G4=(0-2) CH2
REP G5=(0-6) A
VAR G6=ME/CL
VAR G7=30/33
VAR G8=H/37/CF3/38/39/41/42/44/56
VAR G9=H/ME/X
VAR G10=NH2/57
VAR G11=37/38/59/62/44/41/66/68
VAR G12=38/59/62/44/41
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 8
CONNECT IS E1 RC AT 37
CONNECT IS E1 RC AT 38
CONNECT IS E2 RC AT 39
CONNECT IS E1 RC AT 40
CONNECT IS E1 RC AT 64
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 27
GGCAT IS UNS AT 29
GGCAT IS SAT AT 37
GGCAT IS SAT AT 38
GGCAT IS LIN SAT AT 39
GGCAT IS SAT AT 40
GGCAT IS UNS AT 41
GGCAT IS UNS AT 43
GGCAT IS SAT AT 64
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS X2 C AT 39

GRAPH ATTRIBUTES:
RSPEC 44 50
NUMBER OF NODES IS 70

STEREO ATTRIBUTES: NONE
L2 STR



```
VAR G1=ME/CL
REP G4=(0-2) CH2
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   3
DEFAULT MLEVEL IS ATOM
GGCAT   IS PCY  UNS  AT   8
GGCAT   IS UNS  AT  10
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS  10

STEREO ATTRIBUTES: NONE
L3              SCR 7 OR 21
L4          331 SEA FILE=REGISTRY SSS FUL L3 AND L2 AND L1
L6              STR
```



Page 1-A



Page 2-A

```
VAR G6=ME/CL
VAR G7=30/33
VAR G8=H/37/CF3/38/39/41/42/44/56
VAR G9=H/ME/X
VAR G10=NH2/57
VAR G11=37/38/59/62/44/41/66/68
VAR G12=38/59/62/44/41
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   8
CONNECT IS E1  RC AT  37
CONNECT IS E1  RC AT  38
CONNECT IS E2  RC AT  39
CONNECT IS E1  RC AT  40
CONNECT IS E1  RC AT  64
DEFAULT MLEVEL IS ATOM
GGCAT   IS SAT  AT  37
GGCAT   IS SAT  AT  38
GGCAT   IS LIN  SAT  AT  39
GGCAT   IS SAT  AT  40
GGCAT   IS UNS  AT  41
GGCAT   IS UNS  AT  43
GGCAT   IS SAT  AT  64
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X2 C  AT  39

GRAPH ATTRIBUTES:
RSPEC  44  50
NUMBER OF NODES IS  60

STEREO ATTRIBUTES: NONE
L8          128 SEA FILE=REGISTRY SUB=L4 SSS FUL L6
L9            4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8


=> fil wpix
FILE 'WPIX' ENTERED AT 15:26:39 ON 26 NOV 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE LAST UPDATED:          21 NOV 2008   <20081121/UP>
MOST RECENT UPDATE:           200875      <200875/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.2 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to end of
    September 2008. No update date (UP) has been created for the
    reclassified documents, but they can be identified by 20060101/UPIC,
    and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC, 20071130/UPIC,
    20080401/UPIC, 20080701/UPIC and 20081001/UPIC.
    ECLA reclassifications to mid August and US national classification
    mid September 2008 have also been loaded. Update dates 20080401,
    20080701 and 20081001/UPEC and /UPNC have been assigned to these. <<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdates/

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
```

http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0608.pdf

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

=> d que l19
L1 STR



Page 1-A



Page 2-A
VAR G1=23-2 25-3/25-2 23-3/18-2 22-3
REP G2=(0-2) A
REP G4=(0-2) CH2
REP G5=(0-6) A
VAR G6=ME/CL
VAR G7=30/33
VAR G8=H/37/CF3/38/39/41/42/44/56
VAR G9=H/ME/X
VAR G10=NH2/57
VAR G11=37/38/59/62/44/41/66/68
VAR G12=38/59/62/44/41
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 8
CONNECT IS E1 RC AT 37

```
CONNECT IS E1  RC AT  38
CONNECT IS E2  RC AT  39
CONNECT IS E1  RC AT  40
CONNECT IS E1  RC AT  64
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT  27
GGCAT   IS UNS  AT  29
GGCAT   IS SAT  AT  37
GGCAT   IS SAT  AT  38
GGCAT   IS LIN  SAT  AT  39
GGCAT   IS SAT  AT  40
GGCAT   IS UNS  AT  41
GGCAT   IS UNS  AT  43
GGCAT   IS SAT  AT  64
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X2 C  AT  39

GRAPH ATTRIBUTES:
RSPEC  44  50
NUMBER OF NODES IS  70

STEREO ATTRIBUTES: NONE
L2              STR
```




```
VAR G1=ME/CL
REP G4=(0-2) CH2
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   3
DEFAULT MLEVEL IS ATOM
GGCAT   IS PCY  UNS  AT   8
GGCAT   IS UNS  AT  10
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   2
NUMBER OF NODES IS  10

STEREO ATTRIBUTES: NONE
L6              STR
```



Page 1-A



Page 2-A
VAR G6=ME/CL
VAR G7=30/33
VAR G8=H/37/CF3/38/39/41/42/44/56
VAR G9=H/ME/X
VAR G10=NH2/57
VAR G11=37/38/59/62/44/41/66/68
VAR G12=38/59/62/44/41
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 8
CONNECT IS E1 RC AT 37
CONNECT IS E1 RC AT 38
CONNECT IS E2 RC AT 39
CONNECT IS E1 RC AT 40
CONNECT IS E1 RC AT 64
DEFAULT MLEVEL IS ATOM
GGCAT IS SAT AT 37
GGCAT IS SAT AT 38
GGCAT IS LIN SAT AT 39

```
GGCAT   IS SAT  AT  40
GGCAT   IS UNS  AT  41
GGCAT   IS UNS  AT  43
GGCAT   IS SAT  AT  64
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X2 C  AT  39

GRAPH ATTRIBUTES:
RSPEC  44  50
NUMBER OF NODES IS  60

STEREO ATTRIBUTES: NONE
L18         103 SEA FILE=WPIX SSS FUL L1 AND L2 AND L6
L19           3 SEA FILE=WPIX ABB=ON  PLU=ON  L18/DCR


=> dup rem l9 l19
FILE 'CAPLUS' ENTERED AT 15:26:47 ON 26 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 15:26:47 ON 26 NOV 2008
COPYRIGHT (C) 2008 THOMSON REUTERS
PROCESSING COMPLETED FOR L9
PROCESSING COMPLETED FOR L19
L22             4 DUP REM L9 L19 (3 DUPLICATES REMOVED)
                  ANSWERS '1-4' FROM FILE CAPLUS

=> d l22 ibib abs hitstr tot

L22  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2008 ACS on STN  DUPLICATE 1
ACCESSION NUMBER:         2007:14480  CAPLUS  Full-text
DOCUMENT NUMBER:          146:121821
TITLE:                    Preparation of bicyclic derivatives as p38 kinase
                          inhibitors
INVENTOR(S):              Almansa Rosales, Carmen; Virgili Bernado, Marina
PATENT ASSIGNEE(S):       J. Uriach y Compania S.A., Spain
SOURCE:                   PCT Int. Appl., 80pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ----------------    ----   --------    --------------------    --------
     WO 2007000339        A1    20070104    WO 2006-EP6255          20060628
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
             SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
             US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
```

AU 2006263961	A1	20070104	AU 2006-263961		20060628
CA 2613720	A1	20070104	CA 2006-2613720		20060628
EP 1917241	A2	20080507	EP 2006-776093		20060628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, RS					
NO 2007005987	A	20080111	NO 2007-5987		20071123
MX 2007015531	A	20080306	MX 2007-15531		20071207
KR 2008028870	A	20080402	KR 2007-729139		20071213
CN 101208301	A	20080625	CN 2006-80023005		20071226
IN 2007CN06046	A	20080613	IN 2007-CN6046		20071231
PRIORITY APPLN. INFO.:			EP 2005-380140	A	20050629
			WO 2006-EP6255	W	20060628

OTHER SOURCE(S): MARPAT 146:121821

GI



I

II

AB Title compds. represented by the formula I [wherein A = CR1R2 or NR3; R1, R2 = alkyl; R3, R8 = independently -(CH2)p-Cy1 or (un)substituted alkyl; m = 1 or 2; R4 = -B-R8; R5 = H, halo, alkyl or alkoxy; R6 = halo or Me; p = 0-2; Cy1 = (un)substituted Ph, heteroaryl, cycloalkyl or heterocyclyl; B = -CONR9-, -NR9CO- or -NR9CONR9-; R9 = H or alkyl; or salts thereof] were prepared as p38 kinase inhibitors. For example, II was provided in a multi-step synthesis starting from 4-bromo-2-methylbenzoic acid. I showed more than 50 % inhibition for p38α enzyme activity at 10 μM. Thus, I are useful for the treatment of p38 kinase mediated diseases, such as immune diseases.

IT 918332-35-1P, N-Cyclopropyl-4-methyl-3-[2-(3-nitrobenzyl)-1-oxo-2,3-dihydroisoindolin-5-yl]benzamide 918332-61-3P, 3-[2-(3-Aminobenzyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-N-cyclopropyl-4-methylbenzamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of bicyclic derivs. as p38 kinase inhibitors)

RN 918332-35-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-[(3-nitrophenyl)methyl]-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-61-3 CAPLUS
CN Benzamide, 3-[2-[(3-aminophenyl)methyl]-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)



IT 918331-99-4P, N-Cyclopropyl-4-methyl-3-(1-oxo-2-phenyl-2,3-dihydroisoindolin-5-yl)benzamide 918332-00-0P, N-(Cyclopropylmethyl)-4-methyl-3-(1-oxo-2-phenyl-2,3-dihydroisoindolin-5-yl)benzamide 918332-01-1P, 3-(2-Benzyl-1-oxo-2,3-dihydroisoindolin-5-yl)-N-cyclopropyl-4-methylbenzamide 918332-02-2P, 3-(2-Benzyl-1-oxo-2,3-dihydroisoindolin-5-yl)-N-(cyclopropylmethyl)-4-methylbenzamide 918332-07-7P, N-Cyclopropyl-3-[2-(2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-08-8P, N-Cyclopropyl-3-[2-(2-hydroxy-5-sulfamoylphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-09-9P, N-Cyclopropyl-3-[2-(3-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-10-2P, N-Cyclopropyl-3-[2-(2-hydroxy-6-methylphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-11-3P, N-Cyclopropyl-4-methyl-3-[1-oxo-2-(thiazol-2-yl)-2,3-dihydroisoindolin-5-yl]benzamide 918332-12-4P, N-Cyclopropyl-3-[2-(4-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-13-5P, 4-Chloro-N-cyclopropyl-3-[2-(2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]benzamide 918332-14-6P, N-Cyclopropyl-3-[2-(5-chloro-2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-15-7P, N-Cyclopropyl-3-[2-(4-chloro-2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-34-0P, N-Cyclopropyl-4-methyl-3-[1-oxo-2-[(pyridin-4-yl)methyl]-2,3-dihydroisoindolin-5-yl]benzamide 918332-36-2P, 3-[2-(3-Cyanophenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-N-cyclopropyl-4-methylbenzamide 918332-37-3P, N-Cyclopropyl-4-methyl-3-[2-[3-(morpholin-4-yl)phenyl]-1-oxo-2,3-dihydroisoindolin-5-yl]benzamide 918332-38-4P, 3-[2-(Biphenyl-3-yl)-1-oxo-2,3-dihydroisoindolin-5-yl]-N-cyclopropyl-4-

methylbenzamide 918332-41-9P,
N-Cyclopropyl-4-methyl-3-[1-oxo-2-[2-(pyridin-3-yl)ethyl]-2,3-dihydroisoindolin-5-yl]benzamide 918332-42-0P,
N-Cyclopropyl-3-[2-(indazol-6-yl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-43-1P,
N-Cyclopropyl-3-[2-(indol-5-yl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-45-3P,
N-Cyclopropyl-3-[2-(6-methoxypyridin-3-yl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-47-5P,
N-Cyclopropyl-3-[2-(2-methoxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-48-6P,
N-Cyclopropyl-5-fluoro-3-[2-(2-hydroxyphenyl)-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide 918332-50-0P,
2-Cyclopropyl-N-[4-methyl-3-(1-oxo-2-phenyl-2,3-dihydroisoindolin-5-yl)phenyl]acetamide 918332-52-2P,
N-[4-Methyl-3-(1-oxo-2-phenyl-2,3-dihydroisoindolin-5-yl)phenyl]furan-3-carboxamide 918332-62-4P,
N-Cyclopropyl-3-[2-[3-[(methylsulfonyl)amino]benzyl]-1-oxo-2,3-dihydroisoindolin-5-yl]-4-methylbenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic derivs. as p38 kinase inhibitors)

RN 918331-99-4 CAPLUS
CN Benzamide, N-cyclopropyl-3-(2,3-dihydro-1-oxo-2-phenyl-1H-isoindol-5-yl)-4-methyl- (CA INDEX NAME)



RN 918332-00-0 CAPLUS
CN Benzamide, N-(cyclopropylmethyl)-3-(2,3-dihydro-1-oxo-2-phenyl-1H-isoindol-5-yl)-4-methyl- (CA INDEX NAME)



RN 918332-01-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-1-oxo-2-(phenylmethyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-02-2 CAPLUS
CN Benzamide, N-(cyclopropylmethyl)-3-[2,3-dihydro-1-oxo-2-(phenylmethyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-07-7 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(2-hydroxyphenyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-08-8 CAPLUS
CN Benzamide, 3-[2-[5-(aminosulfonyl)-2-hydroxyphenyl]-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 918332-09-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(3-hydroxyphenyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-10-2 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(2-hydroxy-6-methylphenyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-11-3 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-1-oxo-2-(2-thiazolyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-12-4 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(4-hydroxyphenyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-13-5 CAPLUS
CN Benzamide, 4-chloro-N-cyclopropyl-3-[2,3-dihydro-2-(2-hydroxyphenyl)-1-oxo-1H-isoindol-5-yl]- (CA INDEX NAME)



RN 918332-14-6 CAPLUS
CN Benzamide, 3-[2-(5-chloro-2-hydroxyphenyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 918332-15-7 CAPLUS
CN Benzamide, 3-[2-(4-chloro-2-hydroxyphenyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 918332-34-0 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-1-oxo-2-(4-pyridinylmethyl)-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-36-2 CAPLUS
CN Benzamide, 3-[2-(3-cyanophenyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 918332-37-3 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-[3-(4-morpholinyl)phenyl]-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-38-4 CAPLUS
CN Benzamide, 3-(2-[1,1'-biphenyl]-3-yl-2,3-dihydro-1-oxo-1H-isoindol-5-yl)-N-cyclopropyl-4-methyl- (CA INDEX NAME)



RN 918332-41-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-1-oxo-2-[2-(3-pyridinyl)ethyl]-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-42-0 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(1H-indazol-6-yl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-43-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(1H-indol-5-yl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-45-3 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(6-methoxy-3-pyridinyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-47-5 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(2-methoxyphenyl)-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



RN 918332-48-6 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-(2-hydroxyphenyl)-1-oxo-1H-isoindol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)



RN 918332-50-0 CAPLUS
CN Cyclopropaneacetamide, N-[3-(2,3-dihydro-1-oxo-2-phenyl-1H-isoindol-5-yl)-4-methylphenyl]- (CA INDEX NAME)



RN 918332-52-2 CAPLUS
CN 3-Furancarboxamide, N-[3-(2,3-dihydro-1-oxo-2-phenyl-1H-isoindol-5-yl)-4-methylphenyl]- (CA INDEX NAME)



RN 918332-62-4 CAPLUS
CN Benzamide, N-cyclopropyl-3-[2,3-dihydro-2-[[3-[(methylsulfonyl)amino]phenyl]methyl]-1-oxo-1H-isoindol-5-yl]-4-methyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:732641 CAPLUS Full-text

DOCUMENT NUMBER: 143:211908
TITLE: Preparation of fused heteroaryl derivatives as p38 kinase inhibitors
INVENTOR(S): Patel, Vipulkumar Kantibhai; Swanson, Stephen
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073217	A1	20050811	WO 2005-GB266	20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1709028	A1	20061011	EP 2005-702023	20050127
EP 1709028	B1	20081105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007519693	T	20070719	JP 2006-550295	20050127
US 20070054942	A1	20070308	US 2006-587613	20060728
PRIORITY APPLN. INFO.:			GB 2004-2138 A	20040130
			WO 2005-GB266 W	20050127

OTHER SOURCE(S): CASREACT 143:211908; MARPAT 143:211908
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring, R1 = Me or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H, cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo] and their pharmaceutically acceptable salts, are prepared and disclosed as p38 kinase inhibitors. Thus, e.g., II was prepared by palladium catalyzed coupling of 6-bromo-5-fluoro-3-(4-pyridinyl)-1H-indazole (preparation given) with N-cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide. The activity of I was evaluated in fluorescence anisotropy kinase binding assays and it was revealed that compds. of the invention displayed IC50 values of <10 μM or pKi values of >6. I as p38 kinase inhibitor should prove useful in the treatment of disease states mediated by p38 kinase. Pharmaceutical compns. comprising I are disclosed.

IT 862098-61-1P 862098-63-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)

RN 862098-61-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[5-fluoro-3-(4-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 862098-63-3 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-[5-fluoro-3-(4-pyridinyl)-1,2-benzisoxazol-6-yl]-4-methyl- (CA INDEX NAME)



IT 862098-62-2P 862098-64-4P 862098-65-5P
862098-66-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)
RN 862098-62-2 CAPLUS
CN Benzamide, N-cyclopropyl-3-[5-fluoro-3-(1-oxido-4-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 862098-64-4 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-[5-fluoro-3-(1-oxido-4-pyridinyl)-1,2-benzisoxazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 862098-65-5 CAPLUS
CN Benzamide, N-ethyl-3-[5-fluoro-3-(6-methoxy-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 862098-66-6 CAPLUS
CN Benzamide, 3-[3-(6-chloro-3-pyridinyl)-5-fluoro-1H-indazol-6-yl]-N-ethyl-4-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2005:729633 CAPLUS Full-text
DOCUMENT NUMBER: 143:211906
TITLE: Preparation of fused heteroaryl derivatives as p38 kinase inhibitors
INVENTOR(S): Bamborough, Paul; Campos, Sebastien Andre; Patel, Vipulkumar Kantibhai; Swanson, Stephen; Walker, Ann Louise
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073189	A1	20050811	WO 2005-GB265	20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1708996	A1	20061011	EP 2005-702022	20050127
EP 1708996	B1	20080827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007519692	T	20070719	JP 2006-550294	20050127
AT 406351	T	20080915	AT 2005-702022	20050127
PRIORITY APPLN. INFO.:			GB 2004-2143 A	20040130
			WO 2005-GB265 W	20050127

OTHER SOURCE(S): CASREACT 143:211906; MARPAT 143:211906

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring, R1 = Me or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H, cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo] and their pharmaceutically acceptable salts, are prepared and disclosed as p38 kinase inhibitors. Thus, e.g., II was prepared by palladium catalyzed Suzuki coupling of 5-bromo-1-phenyl-1H-indazole (preparation given) with {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid. The activity of I was evaluated in fluorescence anisotropy kinase binding assays and it was revealed that compds. of the invention displayed IC50 values of <10 μM or pKi values of >6. I as p38 kinase inhibitor should prove useful in the treatment of disease states mediated by p38 kinase. Pharmaceutical compns. comprising I are disclosed.

IT 861904-32-7P 861904-72-5P 861904-73-6P
861904-94-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)

RN 861904-32-7 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-72-5 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-pyridinylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-73-6 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(4-pyridinylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-94-1 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(2-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)



IT 861904-25-8P 861904-26-9P 861904-27-0P
861904-28-1P 861904-29-2P 861904-30-5P
861904-31-6P 861904-33-8P 861904-34-9P
861904-35-0P 861904-36-1P 861904-37-2P

861904-38-3P 861904-39-4P 861904-40-7P
861904-41-8P 861904-42-9P 861904-43-0P
861904-44-1P 861904-45-2P 861904-46-3P
861904-47-4P 861904-48-5P 861904-49-6P
861904-50-9P 861904-51-0P 861904-52-1P
861904-53-2P 861904-54-3P 861904-56-5P
861904-57-6P 861904-58-7P 861904-59-8P
861904-60-1P 861904-62-3P 861904-64-5P
861904-66-7P 861904-67-8P 861904-68-9P
861904-69-0P 861904-70-3P 861904-71-4P
861904-75-8P 861904-76-9P 861904-77-0P
861904-78-1P 861904-79-2P 861904-80-5P
861904-81-6P 861904-82-7P 861904-83-8P
861904-84-9P 861904-85-0P 861904-86-1P
861904-87-2P 861904-88-3P 861904-89-4P
861904-90-7P 861904-91-8P 861904-92-9P
861904-93-0P 861904-95-2P 861904-96-3P
861904-97-4P 861904-98-5P 861904-99-6P
861905-00-2P 861905-01-3P 861905-02-4P
861905-03-5P 861905-04-6P 861905-05-7P
861905-06-8P 861905-07-9P 861905-08-0P
861905-09-1P 861905-10-4P 861905-11-5P
861905-12-6P 861905-13-7P 861905-15-9P
861905-17-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)

RN 861904-25-8 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-26-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)



RN 861904-27-0 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-(4-fluoro-2-methylphenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)



RN 861904-28-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-[1-[(4-fluorophenyl)methyl]-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)



RN 861904-29-2 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[[4-(trifluoromethyl)phenyl]methyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-30-5 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylmethyl)-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-31-6 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(5-methyl-3-isoxazolyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-33-8 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)



RN 861904-34-9 CAPLUS
CN Benzamide, N-cyclobutyl-3-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methyl- (CA INDEX NAME)



RN 861904-35-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(4-morpholinyl)phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-36-1 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(4-morpholinyl)phenyl]-1H-indazol-5-yl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861904-35-0
CMF C28 H27 F N4 O2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 861904-37-2 CAPLUS
CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-38-3 CAPLUS
CN Benzamide, 3-fluoro-N,4-dimethyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-39-4 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-40-7 CAPLUS
CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-propyl- (CA INDEX NAME)



RN 861904-41-8 CAPLUS
CN Benzamide, N-butyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-42-9 CAPLUS
CN Benzamide, N-cyclobutyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-43-0 CAPLUS
CN Benzamide, N-cyclopentyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-44-1 CAPLUS
CN Benzamide, 3-fluoro-4-methyl-N-(1-methylethyl)-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-45-2 CAPLUS
CN Benzamide, N-(cyclopropylmethyl)-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-46-3 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-pyridinyl)-1H-indol-5-yl]- (CA INDEX NAME)



RN 861904-47-4 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-pyridinyl)-1H-indol-5-yl]- (CA INDEX NAME)



RN 861904-48-5 CAPLUS
CN Benzamide, 3-[1-(4-cyanophenyl)-1H-indol-5-yl]-N-cyclopropyl-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-49-6 CAPLUS
CN Benzamide, 3-[1-(3-cyanophenyl)-1H-indol-5-yl]-N-cyclopropyl-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-50-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-51-0 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(trifluoromethyl)phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-52-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(methylsulfonyl)phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-53-2 CAPLUS
CN Benzeneacetamide, 4-[5-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazol-1-yl]-N-methyl- (CA INDEX NAME)



RN 861904-54-3 CAPLUS
CN Benzamide, 3-[1-(4-bromophenyl)-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-56-5 CAPLUS
CN Formic acid, compd. with 3-[1-[4-[(cyclohexylmethyl)amino]phenyl]-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861904-55-4
CMF C31 H33 F N4 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 861904-57-6 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-[4-[[2-(dimethylamino)ethyl]amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-58-7 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-[1-[4-[[2-(dimethylamino)ethyl]amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide (2:1) (CA INDEX NAME)

CM 1

CRN 861904-57-6
CMF C28 H30 F N5 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 861904-59-8 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[(tetrahydro-2H-pyran-4-yl)amino]phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-60-1 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[(tetrahydro-2H-pyran-4-yl)amino]phenyl]-1H-indazol-5-yl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861904-59-8

CMF C29 H29 F N4 O2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 861904-62-3 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[[(tetrahydro-2-furanyl)methyl]amino]phenyl]-1H-indazol-5-yl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861905-17-1
CMF C29 H29 F N4 O2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 861904-64-5 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-fluoro-5-[1-[4-[(2-

methoxyethyl)amino]phenyl]-1H-indazol-5-yl]-4-methylbenzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861904-63-4
CMF C27 H27 F N4 O2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 861904-66-7 CAPLUS
CN Formic acid, compd. with N-cyclopropyl-3-[1-[4-[[3-(dimethylamino)propyl]amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide (2:1) (CA INDEX NAME)

CM 1

CRN 861904-65-6
CMF C29 H32 F N5 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 861904-67-8 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-[4-[(2,3-dihydroxypropyl)amino]phenyl]-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-68-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-(2,6-dimethyl-4-pyrimidinyl)-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-69-0 CAPLUS
CN Benzamide, N-cyclopropyl-3-[1-(1,6-dihydro-6-oxo-4-pyrimidinyl)-1H-indazol-5-yl]-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-70-3 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-[3-(4-methoxyphenyl)-1,2-benzisoxazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-71-4 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-5-[3-(4-hydroxyphenyl)-1,2-benzisoxazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-75-8 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-2-pyridinyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-76-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-3-pyridinyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-77-0 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-4-pyridinyl)methyl]-1H-indazol-5-yl]- (CA INDEX NAME)



RN 861904-78-1 CAPLUS
CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-2-pyrimidinyl- (CA INDEX NAME)



RN 861904-79-2 CAPLUS
CN Benzamide, 3-fluoro-N-(4-fluorophenyl)-4-methyl-5-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-80-5 CAPLUS
CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-3-pyridazinyl- (CA INDEX NAME)



RN 861904-81-6 CAPLUS
CN Benzamide, 3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-1H-pyrazol-3-yl- (CA INDEX NAME)



RN 861904-82-7 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-4-methyl-3-(1-phenyl-1H-indazol-5-yl)- (CA INDEX NAME)



RN 861904-83-8 CAPLUS
CN Benzamide, N-ethyl-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-84-9 CAPLUS
CN Benzamide, N-cyclopropyl-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-85-0 CAPLUS
CN Benzamide, N-ethyl-3-[3-(4-methoxyphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-86-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-[3-(4-methoxyphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-87-2 CAPLUS
CN Benzamide, N-ethyl-3-[3-(6-fluoro-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-88-3 CAPLUS
CN Benzamide, 3-[3-(4-ethoxyphenyl)-1H-indazol-6-yl]-N-ethyl-4-methyl- (CA INDEX NAME)



RN 861904-89-4 CAPLUS
CN Benzamide, N-ethyl-4-methyl-3-[3-[4-(methylsulfonyl)phenyl]-1H-indazol-6-yl]- (CA INDEX NAME)



RN 861904-90-7 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(4-methylphenyl)-1H-indazol-6-yl]- (CA INDEX NAME)



RN 861904-91-8 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-[4-(trifluoromethyl)phenyl]-1H-indazol-6-yl]- (CA INDEX NAME)



RN 861904-92-9 CAPLUS
CN Benzamide, 3-[3-(4-chlorophenyl)-1H-indazol-6-yl]-N-ethyl-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861904-93-0 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-5-[3-(6-methoxy-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-95-2 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(1-oxido-2-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)



RN 861904-96-3 CAPLUS
CN Benzamide, N-(1-ethyl-1H-pyrazol-5-yl)-3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861904-97-4 CAPLUS
CN Benzamide, 3-[3-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-indazol-6-yl]-N-ethyl-4-methyl- (CA INDEX NAME)



RN 861904-98-5 CAPLUS
CN Benzamide, 3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 861904-99-6 CAPLUS
CN Benzamide, 3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl-N-1H-pyrazol-3-yl- (CA INDEX NAME)



RN 861905-00-2 CAPLUS
CN Benzamide, N-ethyl-4-methyl-3-[3-[6-(4-morpholinyl)-3-pyridinyl]-1H-indazol-6-yl]- (CA INDEX NAME)



RN 861905-01-3 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(2-pyrimidinyl)-1H-indazol-6-yl]- (CA INDEX NAME)



RN 861905-02-4 CAPLUS
CN Benzamide, N-ethyl-4-methyl-3-[3-(5-pyrimidinyl)-1H-indazol-6-yl]- (CA INDEX NAME)



RN 861905-03-5 CAPLUS
CN Benzamide, N-ethyl-4-methyl-3-[3-(2-pyrazinyl)-1H-indazol-6-yl]- (CA INDEX NAME)



RN 861905-04-6 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-5-[3-(4-fluoro-2-methoxyphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861905-05-7 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-5-[3-(2-methoxy-3-pyridinyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861905-06-8 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-5-[3-(4-fluoro-2-methylphenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861905-07-9 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(3-pyridinyl)-1H-indazol-6-yl]-
(CA INDEX NAME)



RN 861905-08-0 CAPLUS
CN Benzamide, 3-[3-(3,5-dimethyl-4-isoxazolyl)-1H-indazol-6-yl]-N-ethyl-5-
fluoro-4-methyl- (CA INDEX NAME)



RN 861905-09-1 CAPLUS
CN 3-Pyridinecarboxamide, N-ethyl-6-[6-[5-[(ethylamino)carbonyl]-2-
methylphenyl]-1H-indazol-3-yl]- (CA INDEX NAME)



RN 861905-10-4 CAPLUS
CN Benzamide, N-(1,4-dimethyl-1H-pyrazol-5-yl)-3-fluoro-5-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861905-11-5 CAPLUS
CN Benzamide, N-(1,4-dimethyl-1H-pyrazol-5-yl)-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861905-12-6 CAPLUS
CN Benzamide, N-(3,5-dimethyl-4-isoxazolyl)-3-[3-(4-fluorophenyl)-1H-indazol-6-yl]-4-methyl- (CA INDEX NAME)



RN 861905-13-7 CAPLUS
CN Benzamide, 3-[3-(1,2-dimethyl-1H-imidazol-5-yl)-1H-indazol-6-yl]-N-ethyl-5-fluoro-4-methyl- (CA INDEX NAME)



RN 861905-15-9 CAPLUS
CN Formic acid, compd. with N-ethyl-3-fluoro-4-methyl-5-[3-(2-methyl-4-pyridinyl)-1H-indazol-6-yl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 861905-14-8
CMF C23 H21 F N4 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 861905-17-1 CAPLUS
CN Benzamide, N-cyclopropyl-3-fluoro-4-methyl-5-[1-[4-[[(tetrahydro-2-furanyl)methyl]amino]phenyl]-1H-indazol-5-yl]- (CA INDEX NAME)



```
REFERENCE COUNT:          4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22  ANSWER 4 OF 4  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:732643  CAPLUS  Full-text
DOCUMENT NUMBER:          143:193999
TITLE:                    Preparation of fused heteroaryl derivatives as p38
                          kinase inhibitors
INVENTOR(S):              Campos, Sebastien Andre; Swanson, Stephen; Walker, Ann
                          Louise
PATENT ASSIGNEE(S):       Smithkline Beecham Corporation, USA
SOURCE:                   PCT Int. Appl., 59 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2005073219         A1    20050811    WO 2005-GB281            20050127
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     EP 1745038            A1    20070124    EP 2005-702034           20050127
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV
     JP 2007519695          T     20070719    JP 2006-550298           20050127
     US 20070142372         A1    20070621    US 2006-587614           20060728
PRIORITY APPLN. INFO.:                         GB 2004-2140        A    20040130
                                               WO 2005-GB281       W    20050127
OTHER SOURCE(S):          CASREACT 143:193999; MARPAT 143:193999
GI
```



```
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

AB    Title compds. I [A = (un)substituted fused 5-membered heteroaryl ring, R1 = Me
      or Cl; R2 = NHCOR3 or CONH(CH2)qR4; R3 = H, alkyl, CF3, etc.; R4 = H,
      cycloalkyl, alkyl, etc.; q = 0-2; X and Y independently = H, Me or halo] and
      their pharmaceutically acceptable salts, are prepared and disclosed as p38
      kinase inhibitors.  Thus, e.g., II was prepared by coupling of N-cyclopropyl-
      3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide (preparation given) with 2-
      (bromomethyl)tetrahydro-2H-pyran.  The activity of I was evaluated in
      fluorescence anisotropy kinase binding assays and it was revealed that compds.
      of the invention displayed IC50 values of <10 μM or pKi values of >6.  I as
      p38 kinase inhibitor should prove useful in the treatment of disease states
      mediated by p38 kinase.  Pharmaceutical compns. comprising I are disclosed.
IT    861972-61-4P 861972-62-5P 861972-65-8P
```

861972-66-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused heteroaryl derivs. as p38 kinase inhibitors)

RN 861972-61-4 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 4-[6-[5-[(ethylamino)carbonyl]-2-methylphenyl]-1H-indazol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 861972-62-5 CAPLUS
CN Benzamide, N-ethyl-4-methyl-3-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)



RN 861972-65-8 CAPLUS
CN 1(2H)-Pyridinecarboxylic acid, 4-[6-[5-[(ethylamino)carbonyl]-3-fluoro-2-methylphenyl]-1H-indazol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 861972-66-9 CAPLUS
CN Benzamide, N-ethyl-3-fluoro-4-methyl-5-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indazol-6-yl]- (CA INDEX NAME)




```
REFERENCE COUNT:          1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his nofil

     (FILE 'HOME' ENTERED AT 15:02:02 ON 26 NOV 2008)

     FILE 'REGISTRY' ENTERED AT 15:03:09 ON 26 NOV 2008
                ACT PAGONAKIS790/A
               ---------
L1              STR
L2              STR
L3              SCR 7 OR 21
L4          331 SEA SSS FUL L3 AND L2 AND L1
               ---------

     FILE 'CAPLUS' ENTERED AT 15:03:44 ON 26 NOV 2008
L5           12 SEA ABB=ON  PLU=ON  L4
                D QUE L4
                DIS

     FILE 'REGISTRY' ENTERED AT 15:06:53 ON 26 NOV 2008
L6              STR L1
L7            5 SEA SUB=L4 SSS SAM L6
L8          128 SEA SUB=L4 SSS FUL L6

     FILE 'CAPLUS' ENTERED AT 15:20:41 ON 26 NOV 2008
L9            4 SEA ABB=ON  PLU=ON  L8
L10           1 SEA ABB=ON  PLU=ON  US200!-587790/APPS
L11           0 SEA ABB=ON  PLU=ON  L9 AND L10
                SEL RN L10

     FILE 'REGISTRY' ENTERED AT 15:21:11 ON 26 NOV 2008
L12           1 SEA ABB=ON  PLU=ON  291782-12-2/BI
                D SCA

     FILE 'CAPLUS' ENTERED AT 15:21:54 ON 26 NOV 2008
                E US2006-587790/APPS
                E WO2005-GB265/APPS
L13           1 SEA ABB=ON  PLU=ON  (WO2005-GB265/AP OR WO2005-GB265/PRN)
                SEL RN

     FILE 'REGISTRY' ENTERED AT 15:22:34 ON 26 NOV 2008
L14         239 SEA ABB=ON  PLU=ON  (100-39-0/BI OR 100-63-0/BI OR 1003-03-8/BI
                 OR 10075-50-0/BI OR 107-10-8/BI OR 108-00-9/BI OR 109-12-6/BI
                OR 109-55-7/BI OR 109-73-9/BI OR 109-85-3/BI OR 1194-02-1/BI
                OR 128796-39-4/BI OR 130628-75-0/BI OR 139911-29-8/BI OR
                14331-56-7/BI OR 149104-88-1/BI OR 151681-01-5/BI OR 16114-47-9
```

```
                /BI OR 163105-90-6/BI OR 165245-96-5/BI OR 1679-18-1/BI OR
                169124-35-0/BI OR 1692-25-7/BI OR 17874-79-2/BI OR 179899-07-1/
                BI OR 1820-80-0/BI OR 186498-02-2/BI OR 192443-10-0/BI OR
                192443-34-8/BI OR 192443-35-9/BI OR 19847-10-0/BI OR 201733-56-
                4/BI OR 220769-83-5/BI OR 22195-47-7/BI OR 22237-13-4/BI OR
                2516-34-9/BI OR 2516-47-4/BI OR 261953-36-0/BI OR 29939-37-5/BI
                 OR 31329-64-3/BI OR 313350-36-6/BI OR 31519-62-7/BI OR
                3218-02-8/BI OR 32637-62-0/BI OR 350-28-7/BI OR 351019-18-6/BI
                OR 3524-49-0/BI OR 352530-44-0/BI OR 3528-58-3/BI OR 368-90-1/B
                I OR 371-40-4/BI OR 38041-19-9/BI OR 39901-94-5/BI OR 402-49-3/
                BI OR 40929-48-4/BI OR 459-46-1/BI OR 4595-61-3/BI OR 4795-29-3
                /BI OR 4916-55-6/BI OR 504424-71-9/BI OR 504424-72-0/BI OR
                515131-35-8/BI OR 536-89-0/BI OR 53857-57-1/BI OR 541540-09-4/B
                I OR 55401-97-3/BI OR 55458-67-8/BI OR 5720-05-8/BI OR
                574758-37-5/BI OR 585544-30-5/BI OR 589-21-9/BI OR 634187-64-7/
                BI OR 651780-02-8/BI OR 651780-48-2/BI OR 651781-09-8/BI OR
                66572-55-2/BI OR 73870-24-3/BI OR 75-31-0/BI OR 75-65-0/BI OR
                76513-69-4/BI OR 79762-54-2/BI OR 823-85-8/BI OR 86051-75-4/BI
                OR 861904-25-8/BI OR 861904-26-9/BI OR 861904-27-0/BI OR
                861904-28-1/BI OR 861904-29-2/BI OR 861904-30-5/BI OR 861904-31
                -6/BI OR 861904-32-7/BI OR 861904-33-8/BI OR 861904-34-9/BI OR
                861904-35-0/BI OR 861904-36-1/BI OR 861904-37-2/BI OR 861904-38
                -3/BI OR 861904-39-4/BI OR 861904-40-7/BI OR 861904-41-8/BI OR
                861904-42-9/BI OR 861904-43-0/BI OR 861904-44-1/BI OR 861904-45
                -2/BI OR 861904-46-3/BI OR 8
L15          86 SEA ABB=ON  PLU=ON  L14 AND L8

     FILE 'CAPLUS' ENTERED AT 15:23:05 ON 26 NOV 2008
L16           1 SEA ABB=ON  PLU=ON  L9 AND L13

     FILE 'WPIX' ENTERED AT 15:23:17 ON 26 NOV 2008
L17          11 SEA SSS SAM L1 AND L2 AND L6
L18         103 SEA SSS FUL L1 AND L2 AND L6
L19           3 SEA ABB=ON  PLU=ON  L18/DCR

     FILE 'BEILSTEIN' ENTERED AT 15:24:43 ON 26 NOV 2008
L20           0 SEA SSS SAM L1 AND L2 AND L6
L21           0 SEA SSS FUL L1 AND L2 AND L6

     FILE 'CAPLUS' ENTERED AT 15:26:14 ON 26 NOV 2008
                D QUE L9

     FILE 'WPIX' ENTERED AT 15:26:39 ON 26 NOV 2008
                D QUE L19

     FILE 'CAPLUS, WPIX' ENTERED AT 15:26:47 ON 26 NOV 2008
L22           4 DUP REM L9 L19 (3 DUPLICATES REMOVED)
                     ANSWERS '1-4' FROM FILE CAPLUS
                D L22 IBIB ABS HITSTR TOT
```